Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasis

Saraceno, Rosita; Schipani, Caterina; Mazzotta, Annamaria; Esposito, Maria; Renzo, Laura Di; Lorenzo, Antonino De; Chimenti, Sergio

doi:10.1016/j.phrs.2008.02.006

Cited by 133 publications

(178 citation statements)

References 23 publications

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…Because the results of this study showed PsO+PsA patients had an increased risk of developing comorbidities, especially cardiovascular diseases (with an elevated risk for hypertension, hyperlipidemia, diabetes mellitus, and coronary heart disease versus PsO‐ and PsA‐free controls), an appropriate therapy in the early stage of PsO/PsA could be taken into consideration not only for its positive effect on articular and cutaneous symptoms, but also for its effect on the various aspects of this complex picture 40, 41, 42. However, therapies that are effective for PsO may not share similar effectiveness for PsA and vice versa.…”

Section: Discussionmentioning

confidence: 96%

Economic and Comorbidity Burden Among Moderate‐to‐Severe Psoriasis Patients with Comorbid Psoriatic Arthritis

Feldman

Zhao

Shi

et al. 2015

Arthritis Care & Research

View full text Add to dashboard Cite

ObjectiveTo compare the prevalence of comorbidities, health care utilization, and costs between moderate‐to‐severe psoriasis (PsO) patients with comorbid psoriatic arthritis (PsA) and matched controls.MethodsAdults ages 18–64 years with concomitant diagnoses of PsO and PsA (PsO+PsA) were identified in the OptumHealth Reporting and Insights claims database between January 2007 and March 2012. Moderate‐to‐severe PsO was defined based on the use of at least one systemic or phototherapy during the 12‐month study period after the index date (randomly selected date after the first PsO diagnosis). Control patients without PsO and PsA were demographically matched 1:1 with PsO+PsA patients. Multivariate regressions were employed to examine PsO/PsA‐related comorbidities, medications, health care utilization, and costs between PsO+PsA patients and controls, adjusting for demographics, index year, insurance type, and non–PsO/PsA‐related comorbidities.ResultsAmong 1,230 matched pairs of PsO+PsA patients and controls, PsO+PsA patients had significantly more PsO/PsA‐related comorbidities, with the top 3 most common in both groups being hypertension (35.8% versus 23.5%), hyperlipidemia (34.6% versus 28.5%), and diabetes mellitus (15.9% versus 10.0%). Compared with controls, PsO+PsA patients had a higher number of distinct prescriptions filled (incidence rate ratio 2.3, P < 0.05); were more likely to have inpatient admissions (odds ratio [OR] 1.6), emergency room visits (OR 1.3), and outpatient visits (OR 62.7) (all P < 0.05); and incurred significantly higher total, pharmacy, and medical costs (adjusted annual cost differences per patient $23,160, $17,696, and $5,077, respectively; all P < 0.01).ConclusionCompared with matched PsO‐ and PsA‐free controls, moderate‐to‐severe PsO patients with comorbid PsA had higher comorbidity and health care utilization and costs.

show abstract

Section: Discussionmentioning

confidence: 96%

Economic and Comorbidity Burden Among Moderate‐to‐Severe Psoriasis Patients with Comorbid Psoriatic Arthritis

Feldman

Zhao

Shi

et al. 2015

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…TNF-a plays a crucial role in the pathogenesis of psoriasis: in fact, psoriatic patients show elevated serum levels of TNF-a which positively correlate with PASI [68] . Moreover, TNF-a levels and plasma levels of adiponectin are negatively correlated [69][70][71] . In psoriasis, TNF-a increases keratinocyte proliferation, pro-inflammatory cytokines' production, expression of vascular endothelial cell adhesion molecules, angiogenesis.…”

Section: Psoriasis and Nafld: Epidemiologymentioning

confidence: 99%

Non-alcoholic fatty liver disease and psoriasis: So far, so near

Ganzetti

Campanati

Offidani

2015

WJH

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory immune-mediated skin diseases which is frequently associated to comorbidities. Non-alcoholic fatty liver disease (NAFLD) is defined as an excessive accumulation of triglycerides in hepatocytes and includes a wide spectrum of liver conditions ranging from relatively benign steatosis to non-alcoholic steatohepatitis with fatty infiltration and lobular inflammation and to cirrhosis and endstage liver disease. Actually, psoriasis is considered a systemic diseases associated to comorbidities, as metabolic syndrome and NAFLD is seen the hepatic manifestation of the metabolic syndrome. The possible link between psoriasis, obesity and metabolic syndrome, which are known risk factors for NAFLD has been recently documented focusing in the crucial role of the adipose tissue in the development of the inflammatory background sharing by the above entities. According to recent data, patients with psoriasis show a greater prevalence of NAFLD and metabolic syndrome than the general population. Moreover, patients with NAFLD and psoriasis are at higher risk of severe liver fibrosis than those with NAFLD and without psoriasis. The link between these pathological conditions appears to be a chronic low-grade inflammatory status. The aim of this review is to focus on the multiple aspects linking NAFLD and psoriasis, only apparently far diseases. Core tip: The review focuses on the multiple physiopathogenetic aspects of the possible link between psoriasis and non-alcoholic fatty liver disease (NAFLD) emphasizing the most recent scientific data. The importance of the multidisciplinary approach to patients affected by psoriasis is underlined and the therapeutic options to treat concomitant psoriasis and NAFLD is discussed evaluating the risk benefit of both biologic and non-biologic therapies.Ganzetti G, Campanati A, Offidani A. Non-alcoholic fatty liver disease and psoriasis: So far, so near. World J Hepatol 2015; 7(3): 315-326 Available from:

show abstract

“…Therefore, elevated levels of TNF-alpha, which are observed in the serum of patients with psoriasis, may also result from the severe inflammatory process in psoriasis as well as from the contribution of other cells in the synthesis of this cytokine [63]. It is interesting that several research studies have shown increased body weight in patients with psoriasis after therapy with anti-TNF--alpha agents [140][141][142].…”

Section: Tumor Necrosis Factor-alpha (Tnf-alpha)mentioning

confidence: 99%

Biochemical markers of psoriasis as a metabolic disease

Gerkowicz

Pietrzak

Szepietowski

et al. 2012

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Psoriasis is a chronic immune mediated inflammatory skin disease with a population prevalence of 2-3%. In recent years, psoriasis has been recognized as a systemic disease associated with metabolic syndrome or its components such as: obesity, insulin resistance, hypertension and atherogenic dyslipidemia. Many bioactive substances have appeared to be related to metabolic syndrome. Based on current literature, we here discuss the possible role of adiponectin, leptin, ghrelin, resistin, inflammatory cytokines, plasminogen activator inhibitor 1, uric acid, C-reactive protein and lipid abnormalities in psoriasis and in metabolic syndrome.

show abstract

Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasis

Cited by 133 publications

References 23 publications

Economic and Comorbidity Burden Among Moderate‐to‐Severe Psoriasis Patients with Comorbid Psoriatic Arthritis

Economic and Comorbidity Burden Among Moderate‐to‐Severe Psoriasis Patients with Comorbid Psoriatic Arthritis

Non-alcoholic fatty liver disease and psoriasis: So far, so near

Biochemical markers of psoriasis as a metabolic disease

Contact Info

Product

Resources

About